J.P. Morgan Sticks to Their Hold Rating for ProKidney (PROK)
J.P. Morgan analyst Anupam Rama reiterated a Hold rating on ProKidney yesterday. The company’s shares closed yesterday at $2.24.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rama covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Replimune Group, and Vera Therapeutics. According to TipRanks, Rama has an average return of -6.4% and a 39.27% success rate on recommended stocks.
ProKidney has an analyst consensus of Moderate Buy, with a price target consensus of $5.60.
PROK market cap is currently $660.1M and has a P/E ratio of -3.74.
Read More on PROK:
Disclaimer & DisclosureReport an Issue
- ProKidney reports Q2 EPS (13c), consensus (14c)
- Prokidney Corp options imply 15.7% move in share price post-earnings
- Prokidney Corp options imply 13.0% move in share price post-earnings
- Prokidney’s REACT Study: A Promising Step for Kidney Disease Treatment
- Largest borrow rate increases among liquid names
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.